EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients

Marco Bucci iD, Ove Almkvist, Marina Bluma, Nicholas J Ashton, Irina Savitcheva, Konstantinos Chiotis, Guglielmo Di Molfetta, Kaj Blennow, Henrik Zetterberg iD, Agneta Nordberg iD

Journal of Neurochemistry · 2025-08 · 169 (8)

DOI: 10.1111/jnc.70182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neurochemistry, online erschienen am 11.08.2025. Verfasst von Marco Bucci und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockho…. Hauptthemen laut MEDLINE: tau Proteins, Amyloid beta-Peptides, Cognitive Dysfunction, Peptide Fragments. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hjärnfonden, Vetenskapsrådet, Swedish State Support for Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is characterized by brain protein depositions, impaired synaptic transmission, and progressive cognitive decline. This clinical study, conducted at the tertiary memory clinic of Karolinska University Hospital in Stockholm, evaluates plasma pTau217 (in comparison to other plasma biomarkers) as a non‐invasive marker for predicting brain amyloid load and cognitive impairment. Uniquely, it integrates plasma biomarkers with cognitive profiling and amyloid PET to assess diagnostic utility across disease stages in a real‐world memory clinic setting. A total of 122 patients underwent extensive clinical examinations, including CSF analysis (used here for clinical diagnosis only), CT/MRI, neuropsychological (NP) testing ( n = 80) and blood biomarker measurements. Prior to PET imaging, 74 patients were diagnosed with MCI among other diagnoses (AD, other dementia, no dementia). Following PET, patients were reclassified into diagnostic groups: MCI Aβ− ( n = 29), MCI Aβ+ ( n = 19), AD ( n = 51), other dementias ( n = 11). ROC analysis evaluated the ability of plasma biomarkers to predict Aβ‐PET positivity. NP test z ‐scores were reduced into principal components (PCs) using PCA. Plasma pTau217 and pTau217/Aβ42 ratio were elevated in Aβ+ patients compared to MCI Aβ‐patients. The ratio distinguished MCI Aβ+ from AD and, together with pTau217, showed the highest predictive value for Aβ positivity in the MCI group among the biomarkers analyzed (AUC 92.8% and 91.4%). Plasma pTau217/Aβ42 ratio was associated with principal component PC2 (“memory encoding and recall”) in MCI Aβ+ ( ρ =0.64, p=0.01) and negatively correlated with RAVL retrieval (PC2) in the same group ( ρ =−0.57 and −0.6, p=0.028 and 0.017, respectively). Additionally, pTau217 correlated with the “Information” z ‐score (PC4) in both AD ( ρ = −0.50, p = 0.005) and MCI Aβ+ ( ρ = 0.53, p = 0.042). Plasma pTau217/Aβ42 might be a valuable predictor of brain amyloid pathology and a potential marker of domain‐specific cognitive impairment in AD. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsAmyloid beta-PeptidesCognitive DysfunctionPeptide FragmentsCognitionHumansMaleFemaleBiomarkersAgedMiddle AgedAlzheimer DiseaseAged, 80 and overPositron-Emission TomographyNeuropsychological Tests

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid betaneuropsychological testingplasma biomarkerstau

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkersamyloid beta-protein (1-42)Peptide FragmentsMAPT protein, human

Autor:innen und Institutionen

  • Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden.
  • Turku PET Centre, Turku University Central Hospital and University of Turku, Turku, Finland.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.
  • Medical Radiation Physics and Nuclear Medicine, Karolinska University, Stockholm, Sweden.
  • Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

ORCID-Profile: Marco Bucci, Henrik Zetterberg, Agneta Nordberg

Förderung

  • Hjärnfonden
  • Vetenskapsrådet
  • Swedish State Support for Clinical Research
  • European Union's Horizon Europe research and innovation programme
  • KI private bequest (A Nordberg)
  • Fondation pour la Recherche sur Alzheimer
  • Family Kaudert donation
  • Region Stockholm KI CIMED

Zitieren

APA

Bucci, M., Almkvist, O., Bluma, M., Ashton, N. J., Savitcheva, I., Chiotis, K., Di Molfetta, G., Blennow, K., Zetterberg, H., & Nordberg, A. (2025). Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients. Journal of Neurochemistry, 169(8). https://doi.org/10.1111/jnc.70182

Vancouver

Bucci M, Almkvist O, Bluma M, Ashton NJ, Savitcheva I, Chiotis K, et al. Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients. Journal of Neurochemistry. 2025;169(8). doi:10.1111/jnc.70182

BibTeX
@article{Bucci2025,
  author = {Bucci, Marco and Almkvist, Ove and Bluma, Marina and Ashton, Nicholas J and Savitcheva, Irina and Chiotis, Konstantinos and Di Molfetta, Guglielmo and Blennow, Kaj and Zetterberg, Henrik and Nordberg, Agneta},
  title = {Profiling Plasma Biomarkers, Particularly pTau217 and pTau217/Aβ42, and Their Relation to Cognition in Memory Clinic Patients},
  journal = {Journal of Neurochemistry},
  year = {2025},
  volume = {169},
  number = {8},
  doi = {10.1111/jnc.70182}
}
Kostenlos starten →